Phase 2
💊 Investigational Drug / Biologic
NCT04966663
Using ctDNA to Determine Therapies for Lung Cancer
📍 Princess Margaret Cancer Centre — Toronto, Ontario
View Study & Screener ➔11 Recruiting Carcinoma, Non-Small-Cell Lung Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA.
📍 Find Near Me with Distance Radius
Phase 3
💊 Investigational Drug / Biologic
NCT06170788
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
📍 Mayo Clinic in Arizona - Phoenix ( Site 0147) — Phoenix, Arizona
View Study & Screener ➔
Phase 3
💊 Investigational Drug / Biologic
NCT06793215
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
📍 Alaska Oncology and Hematology — Anchorage, Alaska
View Study & Screener ➔
Phase 1
💊 Investigational Drug / Biologic
NCT07094113
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
📍 City of Hope National Medical Center — Duarte, California
View Study & Screener ➔
Phase 1
💊 Investigational Drug / Biologic
NCT04486833
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
📍 Valkyrie Clinical Trials — Los Angeles, California
View Study & Screener ➔
Not Applicable
📊 Observational Clinical Research
NCT03774758
Biomarkers for Risk Stratification in Lung Cancer
📍 Zuckerberg San Francisco General Hospital and Trauma Center — San Francisco, California
View Study & Screener ➔
Phase 1
💊 Investigational Drug / Biologic
NCT06706076
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
📍 Mayo Clinic Hospital - Arizona — Phoenix, Arizona
View Study & Screener ➔
Protocol / Phase N/A
🧠 Behavioral & Telehealth Program
NCT03199651
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
View Study & Screener ➔
Phase 2
💊 Investigational Drug / Biologic
NCT07489066
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
📍 Clearview Cancer Institute (Crestwood) — Huntsville, Alabama
View Study & Screener ➔
Not Applicable
📊 Observational Clinical Research
NCT05265429
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Screener ➔
Phase 3
💊 Investigational Drug / Biologic
NCT07222566
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Pioneer Research Center — Bullhead City, Arizona
View Study & Screener ➔Frequently Asked Questions: Carcinoma, Non-Small-Cell Lung Clinical Trials
How do I qualify for a Carcinoma, Non-Small-Cell Lung clinical trial?
Qualification depends on diagnostic staging, prior therapies, and health stability. Use our preliminary self-screener on individual study pages.
Are trial treatments covered by insurance?
Under federal ACA § 2709, routine patient care costs are covered by health insurance. Review the study Informed Consent document with your doctor for details.